Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
TAUNS Laboratories, Inc. (197A.T)
JPY467.00
-1.00 (-0.21%)
JP JPX Healthcare Medical - Specialties
Address
761-1 Kamishima
Izunokuni, JP
Izunokuni, JP
CEO
Masaki Nonaka
Website
tauns.co.jp
IPO
2024-06-20
ISIN JP3452250008
Description
TAUNS Laboratories, Inc. is a company dedicated to the creation and production of in-vitro diagnostic pharmaceuticals and various types of measuring equipment. Additionally, the firm facilitates the international trade (import and export) of an extensive selection of instruments, covering industrial, medical, physical, and chemical measurement applications. Founded in April 1987, the company maintains its principal office in Izunokuni, Japan.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
JPY467.00
-1.00 (-0.21%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
325.4K
Beta
0.71
Float Shares
28.18M
Free Float %
26.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.20% | -1.57% | +0.40% | -3.83% | +1.01% | -0.99% | -5.99% | +19.81% | +19.81% | +19.81% | +19.81% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
467.00
DCF (Unlevered)
768.94
+64.7%
DCF (Levered)
641.24
+37.3%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
0% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
2.32
Grey zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
5 / 10
Developing
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
2 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Specialties: +8.3%+1.1% Q1'26: -57.6% (vs Q1'25)
-
EPS growth Medical - Specialties: +10.1%+2.0% Q1'26: -80.2% (vs Q1'25)
-
FCF margin FCF growth · Medical - Specialties: +51.3%+38.3% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Specialties: +12.6%+44.6% ★ Q1'26: +10.8% (vs Q1'25)
-
ROIC Medical - Specialties: +6.6%+28.3% ★ Q1'26: +2.0% (vs Q1'25)
-
Share dilution Medical - Specialties: 0.0%+7.2% Q1'26: -1.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×1.60× Q1'26: 9.11× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 2 Rev. Ana. 1 EPS Ana. |
Jun 2027 1 Rev. Ana. 1 EPS Ana. |
Jun 2028 1 Rev. Ana. 1 EPS Ana. |
Jun 2029 1 Rev. Ana. |
|---|---|---|---|---|---|---|
| Revenue |
18.43B
est: 17.64B (+4.5%)
|
18.63B
est: 19.03B (-2.1%)
|
14.83B
14.28B – 15.71B
-22.1% YoY
|
18.43B
18.13B – 18.93B
+24.3% YoY
|
19.72B
19.36B – 20.09B
+7.0% YoY
|
24.90B
24.48B – 25.57B
+26.2% YoY
|
| EBITDA |
8.65B
est: 9.35B (-7.5%)
|
9.02B
est: 10.09B (-10.6%)
|
7.86B
7.57B – 8.32B
-22.1% YoY
|
9.77B
9.61B – 10.03B
+24.3% YoY
|
10.45B
10.26B – 10.65B
+7.0% YoY
|
13.20B
12.98B – 13.55B
+26.2% YoY
|
| EBIT |
7.97B
est: 8.56B (-6.9%)
|
8.30B
est: 9.24B (-10.1%)
|
7.20B
6.93B – 7.63B
-22.1% YoY
|
8.95B
8.80B – 9.19B
+24.3% YoY
|
9.58B
9.40B – 9.75B
+7.0% YoY
|
12.09B
11.89B – 12.41B
+26.2% YoY
|
| Net Income |
5.77B
est: 5.93B (-2.7%)
|
6.32B
est: 6.57B (-3.9%)
|
5.77B
5.61B – 5.94B
-12.1% YoY
|
4.75B
4.62B – 4.88B
-17.7% YoY
|
5.20B
5.06B – 5.35B
+9.6% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
3.04B
est: 3.35B (-9.1%)
|
4.06B
est: 3.61B (+12.3%)
|
2.82B
2.71B – 2.98B
-22.1% YoY
|
3.50B
3.44B – 3.60B
+24.3% YoY
|
3.75B
3.68B – 3.82B
+7.0% YoY
|
4.73B
4.65B – 4.86B
+26.2% YoY
|
| EPS |
57.74
est: 55.33 (+4.3%)
|
62.07
est: 61.29 (+1.3%)
|
53.50
52.34 – 55.37
-12.7% YoY
|
44.02
43.06 – 45.55
-17.7% YoY
|
48.22
47.17 – 49.90
+9.6% YoY
|
—
— – —
-100.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-01 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 8 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree Japan SmallCap Dividend Fund DFJ | 0.07% | 264.8K | 0.58% |
| 2 | WisdomTree International High Dividend Fund DTH | 0.02% | 135.7K | 0.58% |
| 3 | WisdomTree International Equity Fund DWM | 0.01% | 58.9K | 0.48% |
| 4 | Dimensional - International Core Equity 2 ETF DFIC | 0.00% | 54.7K | 0.22% |
| 5 | Dimensional - International Small Cap ETF DFIS | 0.00% | 9.5K | 0.39% |
| 6 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 9.0K | 0.28% |
| 7 | Dimensional International Sustainability Core 1 ETF DFSI | 0.00% | — | 0.24% |
| 8 | Dimensional - International Core Equity Market ETF DFAI | 0.00% | — | 0.18% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
30.64M
Shares Outstanding
106.43M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hiroyuki Nonaka | Senior Managing Executive Officer of Sales & Marketing Division | — | — |
| Junpei Nagai | GM of Corporate Planning Office & Director | — | — |
| Kazunari Nakaishi | Managing Executive Officer & Head of Overseas Business Promotion Office | — | — |
| Masaki Nonaka | President, CEO & Representative Director | — | male |
| Shinnosuke Anada | Managing Executive Officer & GM of Sales & Marketing Division | — | — |
| Takayuki Ohi | Managing Executive Officer & Head of Production Division | — | — |
| Tetsuro Ohtake | Managing Executive Officer & Head of Development Division | — | — |
| Tomohiko Morita | Managing Executive Officer, GM of Administration & Senior Manager of Accounting Department | — | — |
| Toshisuke Takeshima | Managing Executive Officer & GM of Quality Management Division | — | — |
| Yoshio Uchiyama | Chief Financial Officer, Head of Management Headquarters & Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 197A.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
